Ximbio

0 inventions

Ximbio has not registered any invention yet.

6781 reagents managed

MCF7 AREc32 Cell Line

Invented by Prof Roland Wolf at University of Dundee

Antigen/Gene or Protein Targets: Antioxidant Response Element (ARE)- Luciferase

0 reviews 20 references 1 supplier

Anti-CyclinA [E70.1]

Invented by Julian Gannon at Cancer Research UK London Research Institute: Clare Hall Laboratories

Antigen/Gene or Protein Targets: Cyclin A

0 reviews 1 reference 1 supplier

Anti-CyclinA [E72.1]

Invented by Julian Gannon at Cancer Research UK London Research Institute: Clare Hall Laboratories

IHC IF IP WB

Antigen/Gene or Protein Targets: Cyclin A

0 reviews 4 references 1 supplier

Anti-MBP [R29.6]

Invented by Julian Gannon at Cancer Research UK London Research Institute: Clare Hall Laboratories

$Adapted from Verhoeven et al. 2009. PLoS One. 4(8):e6739. PMID: 19707582 The 17 kDa OmpA degradation band fractionates to the soluble periplasmic fraction. Soluble periplasmic fractions (s) and insoluble cell pellet (i) were prepared as described in Supplementary Materials and Methods. Shown are immunoblots of the strain MC1061ΔOmpA containing constructs expressing full-length OmpA without tag insertion (pGI9) and full length OmpA with a 3xFLAG inserted in Loop 2 (pGV32). The latter protein is present at the expected height in the insoluble fraction, as expected for a properly assembled OM protein. The stronger 17 kDa degradation band is present in the soluble periplasmic fraction instead. Only the relevant portions of the blot are shown. The soluble periplasmic protein MBP (40 kDa), inducible by growth on maltose (0.2%), was used as a fractionation marker. The polyclonal anti-OmpA antibody was used in a 1∶10000 dilution (upper blot) and the monoclonal anti-MBP antibody (Abcam, #ab65) was used at a concentration of 1.8 µg/ml (lower blot).$